P
319.39
0.61 (0.19%)
| Previous Close | 318.78 |
| Volume | 791,873 |
| Price / Earnings (Forward) | 55.56 |
| Price / Sales | 8.36 |
| Price / Book | 8.20 |
| 52 Weeks Range |
| Profit Margin | 3.41% |
| Operating Margin (TTM) | 12.45% |
| Diluted EPS (TTM) | 1.09 |
| Quarterly Revenue Growth (YOY) | 16.30% |
| Quarterly Earnings Growth (YOY) | 256.50% |
| Total Debt/Equity (MRQ) | 18.19% |
| Current Ratio (MRQ) | 6.30 |
| Operating Cash Flow (TTM) | 179.16 M |
| Levered Free Cash Flow (TTM) | 135.83 M |
| Return on Assets (TTM) | 5.82% |
| Return on Equity (TTM) | 3.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Penumbra, Inc. | Mixed | Bullish |
AIStockmoo Score
-1.1
| Analyst Consensus | NA |
| Insider Activity | -3.0 |
| Price Volatility | 1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.05 |
|
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.64% |
| % Held by Institutions | 91.96% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| NARAYAN SHRUTHI | - | 318.43 | -1,230 | -391,669 |
| Aggregate Net Quantity | -1,230 | |||
| Aggregate Net Value ($) | -391,669 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 318.43 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| NARAYAN SHRUTHI | Officer | 15 Sep 2026 | Disposed (-) | 1,230 | 318.43 | 391,669 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |